Maria M. Gaspar
PhD (2005) in Pharmaceutical Technology, Universidade de Lisboa
Auxiliar Researcher in Departmento de Tecnologia Farmacêutica e Farmácia Galénica
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Manuela Gaspar is a team member of the NanoBBB. The research has been focused on design, development and biological evaluation of drug delivery systems for improving the therapeutic index of incorporated molecules in infectious, inflammatory and cancer animal models. Design and characterization of appropriated delivery systems for different routes of administration namely pulmonary, intranasal and parenteral. In vitro and in vivo evaluation of developed nanoformulations. In vitro and in vivo screening of new synthesized molecules with antitumor activity.
Afonso MB, Rodrigues PM, Simão A, Gaspar M, Carvalho T, Nunes P, Banales J, Castro RE, Rodrigues CMP. miRNA-21 is overexpressed in primary biliary cholangitis and contributes to liver injury and necroptosis in bile duct-ligated mice. Cell Death Differ 2018; 25: 857-872.
Sousa A, Santos F, Gaspar MM, Calado S, Pereira JD, Mendes E, Francisco AP, Perry MJ, The selective cytotoxicity of new triazene compounds to human melanoma cells. Bioorganic and Medicinal Chemistry 2017; 25: 3900-3910.
Gaspar DP, Gaspar MM, Eleutério C, Grenha A, Loimil M, Goncalves LMD, Taboada P, Almeida A, Remuñán-López, C. Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery. Molecular Pharmaceutics, 2017; 14: 2977-2990.
Nave M, Castro RE, Rodrigues CMP, Casini A, Soveral G, Gaspar MM, Nanoformulations of a potent copper-based aquaporin inhibitor with cytotoxic effect against cancer cells. Nanomedicine UK 2016; 11: 1817-1830.
Gaspar MM, Calado S, Pereira J, Ferronha H; Correia I, Castro H, Tomás AM, Cruz MEM Targeted Delivery of Paromomycin in Murine Infectious Diseases Through Association to Nano Lipid Systems, Nanomedicine: Nanotechnology, Biology, and Medicine 2015; 11: 1851-1860.